Merck & Co Inc reported a 1 percent drop in quarterly sales, hurt by a strong dollar and the loss of market exclusivity on certain drugs.

However, net income attributable to shareholders rose to $1.17 billion, or 42 cents per share, in the fourth quarter ended Dec. 31 from $976 million, or 35 cents per share, a year earlier.

Sales slipped to $10.12 billion from $10.22 billion, the company said on Thursday.

Here's To Your Health
We're reporting in on the latest in health news, medical research, insurance coverage, plus managing your health and the health of the people you love.
We respect your privacy